---
title: "Vicarious Surgical Updates Executive Severance and Change-in-Control Compensation"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/274560268.md"
datetime: "2026-02-02T21:31:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/274560268.md)
  - [en](https://longbridge.com/en/news/274560268.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/274560268.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/274560268.md) | [繁體中文](https://longbridge.com/zh-HK/news/274560268.md)


# Vicarious Surgical Updates Executive Severance and Change-in-Control Compensation

Vicarious Surgical Inc. has amended its executive compensation agreements for its Chief Executive Officer, Stephen From, and Chief Financial Officer, Sarah Romano. Under the new terms, if Mr. From is terminated without cause or resigns for good reason, he will receive a severance payment equal to one year of his base salary, a pro-rata portion of his target bonus, and COBRA premiums for 12 months. If such termination occurs within three months before or 12 months after a change in control, his severance increases to two times his annual base salary plus pro-rata target bonus and COBRA premiums for 24 months, with full vesting of outstanding time-based equity awards. For Ms. Romano, the agreement provides for severance equal to six months of base salary, a pro-rata portion of her target bonus, and COBRA premiums for six months if terminated without cause or resigning for good reason. In a change in control scenario, she would receive two times her six-month base salary, pro-rata target bonus, COBRA premiums for 12 months, and full vesting of time-based equity awards. All severance is contingent on the execution and non-revocation of a separation agreement with customary terms. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vicarious Surgical Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-010807), on February 02, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [Vicarious Surgical Inc. (RBOT.US)](https://longbridge.com/en/quote/RBOT.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md)
- [iShares US Medical Devices ETF (IHI.US)](https://longbridge.com/en/quote/IHI.US.md)
- [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md)
- [SPDR® S&P Health Care Equipment ETF (XHE.US)](https://longbridge.com/en/quote/XHE.US.md)
- [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md)
- [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md)
- [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md)

## Related News & Research

- [Io Biotech Inc - Files Voluntary Chapter 7 Bankruptcy Petition On March 31, 2026 - SEC Filing](https://longbridge.com/en/news/281187506.md)
- [Perimeter Posts Record 2025 Revenue and Wins FDA Approval for AI Breast Imaging Device](https://longbridge.com/en/news/281274047.md)
- [Onconetix Highlights Realbotix AI Humanoid Robot Delivery Update](https://longbridge.com/en/news/281525623.md)
- [BUZZ-Tempus AI rises after study shows AI-driven alerts improve heart valve treatment](https://longbridge.com/en/news/281390073.md)
- [Canada's Perimeter Medical Imaging prelim Q4 revenue jumps 143%](https://longbridge.com/en/news/281240360.md)